Combination of bleomycin and adriamycin with and without radiation in the treatment of inoperable esophageal cancer. A randomized study
Combination of bleomycin and adriamycin with and without radiation in the treatment of inoperable esophageal cancer. A randomized study
复制标题
博来霉素和阿霉素联合使用或不使用放射治疗无法手术的食管癌。
作者：
K. Kolarić;Željko Maričić;A. Roth;Ivo Dujmovic
在一项前瞻性随机研究中，31 名无法手术的食管癌患者接受了博莱霉素和阿霉素联合治疗，以及这些细胞抑制剂和放射治疗的联合治疗。治疗结果评价显示，单独使用细胞抑制剂治疗的16例患者中，有3例部分缓解，2例病情稳定；在所有其他情况下，疾病都在进展。该组的响应率为 19%。在接受 3600-4000 rad 剂量照射并同时接受相同细胞抑制剂和稍低剂量阿霉素的 15 例患者中，有 3 例完全缓解，6 例部分缓解，4 例疾病稳定，而 2 例疾病进展。有效率为 60%，与接受博来霉素阿霉素组合治疗的组相比具有统计学显着性（P < 0.025）。完全缓解病例的平均缓解时间为 11 个月，部分缓解病例的联合治疗为 5.2 个月，联合化疗为 4.2 个月。患者可以忍受毒副作用，尽管联合治疗方式的毒副作用更严重。治疗期间发现 4 例食管支气管瘘（4 例疾病进展）和 1 例主动脉破裂。这项研究显示了放化疗治疗不能手术的食管癌的优势。
In a prospective randomized study, 31 patients with inoperable esophageal cancer were treated with a combination of bleomycin and adriamycin, and with a combination of these cytostatics and radiation. Evaluation of treatment results showed 3 partial remissions and 2 stable‐disease cases in the group of 16 patients treated by cytostatic drugs alone; in all other cases, the disease progressed. The response rate achieved in this group was 19%. In the group including 15 patients who were irradiated with a dose of 3600–4000 rad and received simultaneously the same cytostatics with a somewhat lower dose of adriamycin, there were 3 complete remissions, 6 partial remissions, and 4 stable‐disease cases, while in 2 cases the disease progressed. The response rate was 60%, which was statistically significant (P < 0.025) when compared with the results achieved by the group receiving the bleomycin adriamycin combination. The average duration of remissions in the complete‐response cases was 11 months, and in the partialresponse cases, 5.2 months with combined treatment, and 4.2 months with combination chemotherapy. The toxic side‐effects were tolerable for the patients, albeit more intensive with the combinedtreatment modality. Four esophagobronchial fistulas (four disease progressions) and one rupture of the aorta were noted during treatment. This study has shown the advantages of chemoradiotherapeutic treatment of inoperable esophageal cancer.